Drug intelligence / Profile preview

adch63 ama1

Development stage: Phase 2
Lead developer: University of Oxford
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AdCh63 AMA1 is a candidate malaria vaccine developed by the University of Oxford. It consists of a chimpanzee adenovirus vector (AdCh63) that has been modified to be non-replicating in humans and engineered to express the Plasmodium falciparum apical membrane antigen 1 (AMA1), which is expressed by the malaria parasite during blood-stage infection. The vaccine is designed to stimulate an immune response against this malaria protein to provide protection against malaria infection. It is often used in a heterologous prime-boost strategy with MVA AMA1.

Other names: Chimpanzee adenovirus 63 apical membrane antigen 1 vaccineAdCh63 + AMA1-University of Oxford-malaria

Targets

AMA1 (Apical membrane antigen 1)

Beyond the preview

Go deeper on adch63 ama1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adch63 ama1.

Explore the full profile